GAMMA Investing LLC Acquires 5,452 Shares of Inogen, Inc (NASDAQ:INGN)

GAMMA Investing LLC boosted its position in shares of Inogen, Inc (NASDAQ:INGN) by 5,738.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,547 shares of the medical technology company’s stock after purchasing an additional 5,452 shares during the period. GAMMA Investing LLC’s holdings in Inogen were worth $400,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. Ameriprise Financial Inc. lifted its holdings in Inogen by 0.6% during the 4th quarter. Ameriprise Financial Inc. now owns 848,980 shares of the medical technology company’s stock valued at $7,785,000 after purchasing an additional 5,148 shares during the last quarter. Bridgeway Capital Management LLC increased its position in Inogen by 4.7% in the 4th quarter. Bridgeway Capital Management LLC now owns 631,230 shares of the medical technology company’s stock valued at $5,788,000 after acquiring an additional 28,517 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Inogen by 25.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company’s stock valued at $5,574,000 after acquiring an additional 123,208 shares in the last quarter. Renaissance Technologies LLC increased its position in Inogen by 17.9% in the 4th quarter. Renaissance Technologies LLC now owns 492,900 shares of the medical technology company’s stock valued at $4,520,000 after acquiring an additional 75,000 shares in the last quarter. Finally, Federated Hermes Inc. increased its position in Inogen by 16.8% in the 4th quarter. Federated Hermes Inc. now owns 404,273 shares of the medical technology company’s stock valued at $3,707,000 after acquiring an additional 58,257 shares in the last quarter. 89.94% of the stock is owned by institutional investors.

Analysts Set New Price Targets

INGN has been the subject of several research reports. Wall Street Zen cut shares of Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Needham & Company LLC upgraded shares of Inogen from a “hold” rating to a “moderate buy” rating and set a $12.00 price objective for the company in a research report on Thursday, May 22nd. Stifel Nicolaus lowered their price target on shares of Inogen from $10.00 to $7.00 and set a “hold” rating for the company in a research report on Thursday, May 8th. Finally, B. Riley began coverage on shares of Inogen in a research report on Monday. They set a “buy” rating and a $14.00 price target for the company.

Inogen Price Performance

Shares of NASDAQ:INGN opened at $6.60 on Friday. Inogen, Inc has a one year low of $5.70 and a one year high of $13.33. The company has a 50 day moving average of $6.64 and a 200-day moving average of $8.26. The stock has a market cap of $177.47 million, a price-to-earnings ratio of -5.74 and a beta of 1.64.

Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.27. The firm had revenue of $82.28 million during the quarter, compared to analysts’ expectations of $79.57 million. Inogen had a negative net margin of 8.08% and a negative return on equity of 14.76%. Equities research analysts anticipate that Inogen, Inc will post -1.73 earnings per share for the current year.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.